Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption, post injection, to enable more effective management of blood glucose levels. This is to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypo and hyperglycaemia.
The double-blind, randomised, three-way cross over Phase I clinical study compares the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments. The trial has been conducted in Austria at an internationally recognised centre of excellence in the field of diabetes research and preliminary results are expected in Q4 2019.
Sarah Howell, Chief Executive Officer at Arecor, said: "The completion of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes. I look forward to reporting the headline data from this Phase I study in due course, the first product in our proprietary development pipeline.”